KOSDAQIT & Software372800

Iteyes

₩2,930▲ 0.17%2026-10-02 close
Market Cap
₩20.3B
Turnover
₩37,618,550
Volume
10,000 shares
Shares out.
7M
PER
—
PBR
1.9×
EPS
-₩1,320
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

01

Report overview

Losses Persist as Firm Bets on H2 Order Rebound

ITeyes has recorded operating and net losses through the first half of 2026 following its swing to loss in 2025, and is now seeking a second-half earnings recovery through a large July order intake and a strategic pivot toward MyData, STO, and AI bio-health platform businesses.

  1. 1

    2025 revenue fell 1.9% year-on-year to KRW 78.05bn while operating profit swung to a loss of KRW 5.39bn, driven by declining Finance core and AI/Bigdata solution revenue plus new-business investment costs

  2. 2

    Both Q1 2026 (-KRW 2.75bn) and Q2 2026 (-KRW 2.07bn) posted net losses attributable to owners, extending the loss streak to five consecutive quarters

  3. 3

    In July alone the company secured roughly KRW 60bn in new projects (about KRW 32bn to be recognized as revenue), centered on public and financial sector projects with the Korea Power Exchange and the Korea Credit Guarantee Foundation Central Council

  4. 4

    The company has secured build-and-operate references across all three core MyData domains—finance, healthcare, and energy—while expanding into the FASTO STO platform and AI bio-health business

  5. 5

    Total equity plunged from KRW 18.16bn in 2024 to KRW 8.41bn in 2025, while the debt ratio rose from 227% to 299%, increasing balance-sheet pressure

02

Business structure

ITeyes was founded in 2012 with the aim of becoming a 'financial IT compliance specialist group' and operates as a finance-focused IT solutions provider.

Its core business centers on developing, building, and operating information systems for specialized financial IT areas such as credit rating, market risk management, asset management, and over-the-counter derivatives, while its self-developed cloud-based digital platform, GURMWI™, extends AI, big data, cloud, and blockchain technologies into other industries.

The company's segments are broadly divided into Finance core solution and AI/Bigdata solution, and revenue declines in both segments were a key driver of the 2025 earnings deterioration.

Its client base spans banks, securities firms, pension funds, and public institutions, with references including system builds and solution supply for KDB Industrial Bank of Korea, IBK Industrial Bank of Korea, Shinhan Life, and Korea Gas Corporation.

More recently, the company has secured build-and-operate references across all three core MyData domains—finance, healthcare, and energy—positioning itself, by its own account, as the only domestic data solutions firm to have executed projects in all three areas simultaneously.

It has also designated the FASTO security token offering (STO) trading solution, developed in cooperation with partners such as Eugene Investment & Securities, and an AI bio-health (precision medicine) platform built on medical MyData as future growth pillars, pursuing a shift from a system-integration-centered business toward a platform service operator.

Competitively, the company coexists with large systems integrators and specialized infrastructure institutions such as the Korea Financial Security Institute and Koscom. Management has stated that its MyData references are expected to serve as a competitive advantage in future project bids.

In scale, the company operates as a small-to-mid-cap KOSDAQ-listed IT services firm with a relatively high ratio of new-business investment to revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q2₩20.5B₩300M1.5%
2025Q3₩20.1B-₩300M−1.5%
2025Q4₩16.2B-₩4.3B−26.7%
2026Q1₩18.7B-₩2.8B−14.8%
2026Q2₩12.9B-₩3B−23.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩54.6B-₩11.3B-₩10B−20.8%−41.1%65.8%
2023₩74.9B-₩6.4B-₩7.1B−8.5%−42.2%179.3%
2024₩79.6B₩200M₩1.4B0.2%8.0%227.0%
2025₩78.1B-₩5.4B-₩9.5B−6.9%−105.8%299.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

04

Earnings analysis

ITeyes' annual revenue rose steadily from KRW 54.57bn in 2022 to KRW 74.95bn in 2023 and KRW 79.58bn in 2024, but declined 1.9% year-on-year to KRW 78.05bn in 2025, breaking the growth trend.

On profitability, the company posted operating margins of -20.8% in 2022 and -8.5% in 2023 before turning profitable in 2024 with operating profit of KRW 166.6mn (a 0.2% margin), only to swing back to an operating loss of KRW 5.39bn (a -6.9% margin) in 2025.

Net income attributable to owners followed the same pattern, moving from a profit of KRW 1.43bn in 2024 to a loss of KRW 9.52bn in 2025.

On a quarterly basis, Q2 2025 posted a modest operating profit of KRW 314mn yet still recorded a net loss attributable to owners of KRW 3.19bn, suggesting non-operating factors played a significant role; Q3 2025 narrowed the loss with revenue of KRW 20.06bn and an operating loss of KRW 296mn, but Q4 2025 saw revenue fall sharply to KRW 16.21bn while the operating loss widened to KRW 4.32bn, driving the annual deterioration.

Losses continued into 2026, with Q1 revenue of KRW 18.70bn, an operating loss of KRW 2.77bn, and a net loss of KRW 2.75bn, followed by Q2 revenue of KRW 12.93bn, an operating loss of KRW 3.00bn, and a net loss of KRW 2.07bn, showing simultaneous revenue contraction and persistent losses.

Cash flow also deteriorated in tandem, with operating cash flow of positive KRW 9.16bn in 2024 reversing to negative KRW 7.98bn in 2025.

Company and industry commentary attribute the profitability decline primarily to upfront investment costs tied to new businesses such as VERAI, AI-based financial service support, a medical MyData application, and the FASTO launch.

05

Industry analysis

Korea's financial IT and public systems integration market continues to see structural demand from the expansion of the MyData system, cloud migration, and AI adoption, but individual companies' quarterly results tend to fluctuate significantly depending on budget allocation timing and project award schedules.

Following its 2025 announcement of transmission procedures and technical guidelines for MyData across all sectors, the government has been expanding the designation of sector-specific relay institutions and related infrastructure budgets, with expectations that the MyData system will extend into telecommunications, real estate, retail, and education.

ITeyes is described as the only domestic company to have secured build-and-operate references across all three core MyData domains—finance, healthcare, and energy—which is seen as giving it a reference advantage in future relay-institution bids for new sectors.

However, such projects are heavily dependent on external variables such as public budget execution timing and standards/security certification procedures, causing revenue recognition to be unevenly distributed across quarters.

Competitively, large systems integrators coexist with specialized infrastructure institutions such as Koscom and the Korea Financial Security Institute, and ITeyes, as a smaller specialized player, positions its accumulated expertise in specific domains—financial risk management and MyData relay—as its competitive edge.

The security token offering (STO) market remains at an early stage of institutional development, with the KDX consortium in which ITeyes participates having obtained preliminary approval for an over-the-counter exchange, leaving further procedural steps before commercialization.

Overall, while the industry itself is viewed as having growth potential, the timing and extent of monetization for individual companies can vary considerably depending on project-specific order intake and revenue recognition structures.

06

Outlook

Building on its large July order intake, the company has formally guided toward an earnings improvement in the second half of 2026.

CEO Lee Sung-nam stated that from August onward, meaningful revenue generation, stable cash flow, and platform business results would become visible together, adding that the company expects to achieve record profit in 2027 on this basis.

The energy MyData relay service project underway with the Korea Energy Agency aims to complete a platform that transmits and relays electricity and gas data in accordance with MyData standard API specifications by the end of this year, making the year-end launch a key point to verify going forward.

The company said it plans to nurture the MyData platform as a separate business line and pursue a recurring-revenue model by turning its relay systems into standardized solutions.

It is also advancing portfolio upgrades around three core growth platforms—a digital finance (STO) platform, an energy trading platform, and an AI bio-health (precision medicine) platform—with the progression from preliminary to full approval for the STO over-the-counter exchange via the KDX consortium, and the commercialization progress of the FASTO platform, likely to serve as gauges of new-business execution.

The company has also pursued external financing, including convertible bond issuance, to fund new-business expansion.

These targets and expectations are based on company statements, however, and the actual timing of revenue recognition and profitability improvement will need to be confirmed through future quarterly disclosures.

07

Valuation

PER
—
PBR
1.9×
ROE
-73.4%
EPS
-₩1,320
BPS
₩1,607
Dividend per share
₩0

Because of net losses in recent fiscal years, a conventional price-to-earnings ratio cannot be meaningfully calculated for ITeyes, and the absence of dividend payments also limits dividend-based comparisons.

Its price-to-book ratio trades in a range that reflects a premium over net asset value, suggesting the market continues to assign a certain level of value even as total equity contracted sharply in 2025 from the prior year.

Looking at the multi-year earnings pattern, the company moved from losses in 2022-2023 to a profit in 2024, then back to a loss in 2025 that has persisted through the first half of 2026, indicating that earnings stability has not yet been established.

As a result, market participants appear to be closely watching whether second-half order wins translate into revenue and profit, along with the pace of platform-business monetization, as key variables for valuation judgment.

Given that the current market capitalization places the stock among the smaller names on KOSDAQ, valuation can be relatively more sensitive to individual events such as large order announcements or new-business milestones.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

08

Bull factors

References Secured Across Three Core MyData Domains

ITeyes is described as the only domestic data solutions company to have secured build-and-operate references across all three core MyData domains—finance, healthcare, and energy.

As the MyData system is expected to expand into telecommunications, real estate, and retail, these references are viewed as a potential competitive advantage in future project bids. The company is using this foundation to nurture the MyData platform as a separate business line and pursue a recurring-revenue model.

July Order Intake Provides Second-Half Revenue Visibility

In July 2026 alone, the company secured new projects worth roughly KRW 60bn in total project value (about KRW 32bn on a revenue-recognition basis), including projects with the Korea Power Exchange and the Korea Credit Guarantee Foundation Central Council.

The company stated it expects revenue generation and cash flow stabilization to become visible from August onward. If these large orders translate into actual revenue, they could positively affect results in the second half of 2026 and into 2027.

New Growth Pillars Through Platform Business Diversification

ITeyes is moving away from a systems-integration-centered business model toward three core growth platforms—a digital finance (STO) platform, an energy trading platform, and an AI bio-health (precision medicine) platform.

It has obtained preliminary approval for an STO over-the-counter exchange through the KDX consortium and is nurturing the FASTO solution, developed with partners such as Eugene Investment & Securities, as a strategic business.

Should these new businesses reach the commercialization stage, they could contribute to greater revenue stability and improved profitability.

09

Bear factors

Five Consecutive Quarters of Net Losses, Deteriorating Balance Sheet

Net income attributable to owners has posted losses for five consecutive quarters, from Q2 2025 through Q2 2026. As a result, total equity plunged from KRW 18.16bn in 2024 to KRW 8.41bn in 2025, and the debt ratio rose from 227% to 299%. Further accumulated losses could heighten concerns about financial capacity.

Revenue Contraction and Earnings Volatility

Q2 2026 revenue of KRW 12.93bn fell sharply from KRW 20.49bn in Q2 2025, and quarterly revenue and operating results show considerable variability.

The order-driven revenue structure, centered on public and financial sector projects, is prone to fluctuation depending on award timing, and any delay or reduction in new orders could push back the timing of an earnings recovery.

Sustainability of Upfront New-Business Investment Costs

Upfront investment costs tied to new businesses such as VERAI, the medical MyData app, and FASTO have been cited as a key factor behind the 2025 profitability decline.

These new businesses may require additional investment and time before reaching commercialization and monetization, and if the associated cost burden persists, the timing of a profit recovery could be delayed relative to expectations.

10

Risk factors

Balance Sheet Risk

Total equity fell to less than half of the prior-year level in 2025, and the debt ratio rose to 299%, weakening the company's financial buffer. Further net losses could increase the need for capital raising or external financing, and the company has already issued convertible bonds to fund new-business expansion.

Order Intake and Revenue Recognition Risk

A significant portion of revenue depends on projects ordered by public and financial institutions, making quarterly results highly sensitive to budget execution timing and procurement schedules.

If the timing or scale of revenue recognition from the July order intake differs from plan, expectations for a second-half earnings improvement could shift.

New Business Execution and Regulatory Risk

The STO platform (FASTO) and the KDX consortium business must go through additional institutional procedures, including full approval following preliminary approval, and their timelines could be affected by changes in the regulatory environment.

New businesses such as AI bio-health and energy MyData also require time to reach commercialization and monetization, with a risk that they may not proceed exactly as planned.

11

What to watch next

  1. Mid-November 2026

    The Q3 2026 quarterly report will need to be checked to confirm whether the July large order intake is being reflected in revenue and whether profitability is improving.

  2. December 2026

    It will be important to verify whether the energy MyData relay platform being built with the Korea Energy Agency is completed and formally launched by year-end as planned.

  3. Q4 2026 to early 2027

    Progress on full approval for the KDX consortium's STO over-the-counter exchange and the commercialization status of the FASTO platform will need to be monitored.

  4. Early 2027

    The 2026 annual business report will need to be reviewed to confirm whether the second-half earnings improvement and full-year profitability recovery referenced by the company were actually achieved.

12

Overall view

Following a temporary return to profit in 2024, ITeyes has recorded operating and net losses throughout 2025 and the first half of 2026, indicating that earnings stability has not yet been established.

At the same time, the contraction in total equity and the rise in the debt ratio point to growing balance-sheet pressure.

That said, the roughly KRW 60bn in new orders secured in July and the company's references across the three core MyData domains—finance, healthcare, and energy—are factors the company itself cites as grounds for a second-half and 2027 earnings recovery.

New businesses such as the FASTO STO platform and the AI bio-health initiative remain at an early stage of commercialization and monetization, making the pace of execution and regulatory procedure progress key points to watch going forward.

On balance, this stock's earnings trajectory is shaped by the cycle of public and financial-sector IT project awards and the success or failure of its platform-business transition, putting it in a phase where actual improvement will need to be continuously verified through future quarterly disclosures and new-business progress.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. valueline.co.kr
  2. m.thinkpool.com
  3. m.irgo.co.kr
  4. kr.investing.com
  5. judal.co.kr
  6. google.com
  7. paxnet.co.kr
  8. markets.hankyung.com
  9. jobkorea.co.kr
  10. saramin.co.kr
  11. catch.co.kr
  12. catch.co.kr
  13. comp.fnguide.com
  14. jobkorea.co.kr
  15. saramin.co.kr
  16. incruit.com
  17. m.thinkpool.com
  18. iteyes.co.kr

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.